INTRODUCTION 84 85
The human genome is made of -20,000 protein-coding genes, but not all proteins are suitable drug 86 targets [1] [2] [3] . The druggable proteome can be defined as the percentage of proteins that have the 87 capacity to bind an antibody or small molecule with adequate chemical properties and affinity [4] . 88
Druggability is the property of a druggable molecule (i.e., a biological target) by virtue of which it 89 elicits a favorable clinical response when it contacts a drug-like compound [5] . It is estimated that 60% 90 of the small molecule drug discovery projects fail during the hit-to-lead phase because the biological 91 target is found to be not druggable [5, 6] . Therefore, it is important to be able to predict how druggable 92 a novel target is in early drug discovery because only 10% of the human genome represents druggable 93 targets, and only half of those are relevant to diseases [7] . 94 95 According to Gashaw et al., an ideal drug target should have the following properties: freedom to 96 operate (i.e., lack of competitive binding), the existence of a biomarker to monitor its efficacy, 97 differential expression across the body for specific targeting, low impact on the modulation of 98 physiological conditions, capacity to modify a disease, and favorable assayability for high throughput 99 screening [7, 8] . 100 101 Regarding all the protein-coding genes in the human genome, approximately 3,000 are estimated to be 102 part of the druggable genome. Yet, drugs approved by the US Food & Drug Administration (FDA) 103 target just twenty percent of the druggable proteins [9] . FDA has approved the use of 672 (100%) 104 drugs classified by their protein class in enzymes (260; 39%), transporters (149; 22%), G-protein 105 coupled receptors (98; 15%), CD markers (71; 11%), voltage-gated ion channels (49; 7%), nuclear 106 receptors (24; 4%), among others [10, 11] . Drugs that inactivate the protein target are known as 107
antagonists, while drugs that activate the protein target are called agonists. Regarding the cellular 108 location of targets for FDA approved drugs based on a variety of transmembrane and signal protein 109 prediction methods, 250 (37%) were integral membrane (IM), 201 (30%) were intracellular, 101 (15%) 110 were single pass transmembrane (SPTM), 83 (12%) were secreted, 28 (4%) were membrane and 111 secreted isoforms, and 9 (1%) were IM/SPTM [4, 10, 11] . 112
113
The low number of approved drugs up to date is due to several factors such as the complexity in the 114 experimentation of all proteins and fragments of nucleic acids, and the lack of knowledge of various 115 diseases at molecular level. Due to these facts, computational models that can predict drug targets with 116 high sensitivity while maintaining a high specificity on a genome-wide scale would be highly 117 welcomed [5] . Additionally, it is possible to combine big data such as metabolic and gene regulatory 118 networks, protein-protein interactions, multi-omics information and gene expression profiles with data 119 mining tools like machine learning (ML) to build predictive models in order to identify biological 120 relevant patterns that confer druggability to potential drug targets [12] . neurons, a hidden layer that is able to combine linear and nonlinear activation functions [34] . Decision 163 tree (DT) (DecisionTreeClassifier) is a structure of decision rules inferred from the input features 164 (classification rules = paths from root to leaf) [35] . Random forest (RF) is an ensemble method by 7 combining parallel decision trees and it offers low-bias, low correlation between individual trees, and 166 high variance [36] . 167 168 XGBoost (XGB) is another type of ensemble method but it is using sequential weak trees to correct the 169 classification errors [37] . Gradient Boosting for classification (GB) is a classical boot method based on 170 the same sequential weak classifiers [38] . AdaBoost classifier (AdaB) is a meta-estimator that starts the 171 fitting with a classifier based on the original dataset and then adds additional copies of the original 172 classifier with adjusted weights for the incorrectly classified instances [39] . Bagging classifier 173 (Bagging) is similar with AdaB but the additional classifiers are based on subsets of the original dataset 174
The machine learning prediction model was constructed from two protein sets, the positive set was 177 made up of 666 druggable proteins with FDA-approved drugs according to the DrugBank database 178 (www.drugbank.ca) [10, 11, 42] . On the other hand, the negative protein set was made up of 219 non-179 druggable proteins [43] . Tables S1 and S2 [45], and 1365 were RBPs [45, 46] (Tables S5-S7) . 186
After the calculation of amino acid composition descriptors, the datasets contained 885 proteins (666 187 positive set, 219 negative set). The druggable class was labeled with 1, and the non-druggable class 188 with 0. Due to the unbalanced datasets, a SMOTE filter was used [47] . A 3-fold cross-validation (CV) 189 method was used to build the ML classifiers. A pipeline was constructed for each fold: a) scaler: the 190 training set was scaled with StandardScaler and the test set was transformed to the same scale; b) 191 feature selection / feature dimension reduction: the training set dimensionality was reduced by using or 192 not a feature selection method (i.e., LinearSVC) or a feature dimension reduction (i.e., PCA); c) outer-193 8 CV: cross_val_score has been used to calculate the AUROC scores for the 13 ML methods in all splits; The project is proposing innovative classification models to predict new druggable proteins by using 214 three families of protein composition descriptors calculated with Rcpi: AC, DC and TC. Jupyter 215 notebooks based on python/sklearn were used to build classifiers using 13 types of ML classifiers and 216 five types of feature selection methods, with different parameters (Fig. 1) . The scripts used AUROC to 217 quantify the classification performance. We tested models with 20, 100, 200, 400 and mixed numbers Perc2.5 = TC selected descriptors with SelectPercentile(f_classif, percentile=2.5), TC-LinearSVC200 239 = TC selected with LinearSVC. The same PCA mixed with SVM for DC-PCAn200 are resulting the 240 best classifier with AUROC of 0.981. Additional results could be found in Table S8 . If we will use all 241 400 DC descriptors with SVM, the mean AUROC could reach 0.982 ± 0.0021. Even more, with pure 242 8000 TC and SVM linear, the mean AUROC become 0.992 ± 0.0028. For a classification model, it 243 should be avoided that the number of input features is more than the number of data instances. In 244 addition, we tried to choose pure descriptors, not PCA transformed. Therefore, we made a compromise 245 and we choose as the best model for the next predictions for proteins related to cancer: 200 TC 246 descriptors selected with LinearSVC, non-linear SVM classifier with 0.975 ± 0.003 and accuracy of (Table S9 ). The top 20 BC essential 268 proteins predicted as druggable were CDK4, AP1S1, POLE, HMMR, RPL5, PALB2, TIMP1, RPL22, 269 NFKB1, TOP2A, CTNNB1, BRCA2, TAF1, MLH1, NQO1, TOP3A, PIK3R1, RRM1, CDH1, and 270 MMP2 (Fig. 5C) druggable prediction of BC proteins through ML approaches will provide us relevant information 281 regarding potential biomarkers, therapeutic targets and future clinical trials, avoiding ethnicity bias and 282 improving cancer pharmacogenomics and precision medicine worldwide [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] . binding, and transcription regulatory region DNA binding; the most significant GO: biological 288 processes were positive regulation of macromolecule metabolic process, positive regulation of nitrogen 289 compound metabolic process, and positive regulation of metabolic process; the most significant KEGG 290 pathways were EGFR tyrosine kinase inhibitor resistance, pathway in cancer, and transcriptional 291 misregulation in cancer [51, 52] ; additionally, the most significant term according to the Human 292
Phenotype Ontology was somatic mutation [54] (Table S11 ). The top 20 cancer-driving proteins 293 predicted as druggable were TLL2, FAM47C, SAGE1, HTR1E, MACC1, ZFR2, VMA21, DUSP9, 294 CTNNA3, GABRG1, ZNF608, BIRC6, ARAF, ZNF483, TFRC, PCDHB6, DOCK4, TRPM3, TRAF6 295 and POF1B (Fig. 6C ). Regarding the Open Targets Platform [50] , 17 of 20 best-ranked proteins do not 296 have clinical trials in all cancer types, GABRG1 has 34, TFRC has 10, and ARAF has 2 (Table S12 , 297
Figs. 6C and 6D). For instance, GABR1 has two clinical trials in phase 4 using propofol and 298 sevoflurane, small molecules that belong to the GABA-A receptor class [50] . 299
300
The cancer-driving proteins were taken from The Network of Cancer Genes [45], a manually curated 301 repository whose somatic modifications have known or predicted cancer driver roles. Fig. 7 shows the 302 correlation between the best druggable predicted proteins and the cancer-driving proteins of 25 tissues 303 of different primary sites (full list detailed in Table S13 functions were RNA binding, nucleic acid binding, and heterocyclic compound binding; the most 316 significant GO: biological processes were RNA processing, ribonucleoprotein complex biogenesis, and 317 mRNA metabolic process; the most significant KEGG pathways were spliceosome and ribosome 318 biogenesis in eukaryotes [51, 52] ; finally, the most significant WikiPathway was mRNA processing 319
[53] (Table S14 ). The top 20 RBPs predicted as druggable were PLASG1B, CREB2, NOL6, LRRC47, 320 CTTN, CORO1A, SCAF11, KCTD12, DDX43, TMPO, SARS2, SARNP, MEX3D, ZNF106, MTPAP, 321 PRPF40A, YWHAZ, SEPTIN11, DDX46, and ANXA7 (Fig. 8C) The current study proposed a new prediction model for druggable proteins by using as inputs the amino 338 acid composition descriptors of protein sequences for 13 Machine Learning classifiers (with or without 339 feature selection/dimension reduction of features). The best classifier was provided by SVM using only 340 200 selected tri-amino acid composition descriptors (TC). The high performance of the model is based 341 on a mean AUROC of 0.975 ± 0.003 and a mean accuracy of 0.929 ± 0.006 (3-fold cross-validation). 342
Thousands of protein sequences related to cancer have been used to predict the druggability. The top 343 10 BC OncoOmics essential proteins predicted as druggable were CDK4, AP1S1, POLE, HMMR, 344 RPL5, PALB2, TIMP1, RPL22, NFKB1 and TOP2A; the top 10 cancer-driving proteins predicted as 345 druggable were TLL2, FAM47C, SAGE1, HTR1E, MACC1, ZFR2, VMA21, DUSP9, CTNNA3 and 346 GABRG1; and the top 10 RNA-binding proteins predicted as druggable were PLA2G1B, CPEB2, 347 NOL6, LRRC47, CTTN, CORO1A, SCAF11, KCTD12, DDX43 and TMPO. Nevertheless, most of 348 them do not currently have clinical trials. Finally, this powerful model predicts several druggable 349 proteins which should be deeply studied to find better therapeutic targets and thus improve clinical 
